This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View
by Zacks Equity Research
Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.
Key Predictions for Q3 Earnings Reports of ABBV, MRK
by Zacks Equity Research
The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.
Merck vs. Pfizer: Which is Better Ahead of Q3 Earnings?
by Swarup Gupta
With Merck and Pfizer scheduled to report on Oct 27 and Oct 31, respectively this may be a good time to consider which of these is a better stock.
Is a Beat in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to report third-quarter 2017 on Oct 26.
Can AbbVie (ABBV) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.
Healthcare ETFs Set to Soar as Q3 Earnings Unfold
by Sweta Killa
With earnings surprises well in the cards, healthcare ETFs are set to soar.
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. Approval of Orencia in psoriatic arthritis is also a positive.
Celgene Down on Discontinued Crohn's Disease Drug Study
by Zacks Equity Research
Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.
BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
by Zacks Equity Research
BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.
AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
by Zacks Equity Research
AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
by Zacks Equity Research
J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.
Cancer Space Update: Lung & Breast Cancer Studies in Focus
by Zacks Equity Research
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
Seattle Genetics Inks Clinical Collaborations for Cancer Drug
by Zacks Equity Research
Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.
Seattle Genetics Begins Phase II Study of Cancer Candidate
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
Company News For Oct 11, 2017
by Zacks Equity Research
Companies in the news are: CUDA,MRK,ANAB,HDSN
Here's What's Has Happened in the HCV Space Lately
by Zacks Equity Research
A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
by Zacks Equity Research
Seattle Genetics' (SGEN) lymphoma drug, Adcetris has been granted Breakthrough Therapy Designation by the FDA for treating patients with advanced classical Hodgkin lymphoma with no prior treatments.
Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?
by Arpita Dutt
With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.
Merck Drops Two HCV Combination Programs Amid Competition
by Zacks Equity Research
Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.
Ligand's Captisol Deals Set to Drive Growth in the Long Run
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.
Sanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales Weak
by Zacks Equity Research
Sanofi's (SNY) Genzyme and Vaccines units are driving sales. Sales from the Diabetes franchise however continue to drop.
Agenus (AGEN) Remains Focused on Drug Development Programs
by Zacks Equity Research
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China
by Zacks Equity Research
Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.
Agilent Boosts Market Share With FDA Nod to New Cancer Test
by Zacks Equity Research
Agilent Technologies' (A) recent FDA approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx for UC and SCCHN patients will further expand its share in the growing cancer-diagnostic market.
Impax Generic Division Progresses Well Amid Pricing Pressure
by Zacks Equity Research
Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.